Regorafenib,Nivolumab,Docetaxel,Paclitaxel,Irinotecan,trifluridine tipiracil
Bayer,BMS,Taiho pharma
[]
phiii integrate iia #3l+ rego vs placebo adv #gej cancer w/os benefit hr 0.68 over placebo and improvement in qol deterioration-free survival. amended to include rego + nivo vs. ic chemo in 3l+ integrate iib ongoing, which appears to be more clinically relevant arm #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope